

RESPONSE TO RESTRICTION REQUIREMENT

Please enter the following amendment to the claims prior to examination on the merits.

In the Claims

Please cancel claims 1-5 and 11-18.

27. (amended) An immunogenic composition comprising a peptide molecule selected from the group consisting of PPPGRRP (SEQ ID NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7), GPQRRGGDNHGRGRGRGRGRGGGRP (SEQ ID NO:13), GGSGSGPRHRDGVRRPQKRP (SEQ ID NO:14), RPQKRPS (SEQ ID NO:15), QKRPSIGCKGTHGGTG (SEQ ID NO:16), GTGAGAGARGRG (SEQ ID NO:17), SGGRGRGG (SEQ ID NO:18), RGGSGGRRGRGR (SEQ ID NO:19), RARGRGRGRGEKRPRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID NO:21), RPPPGRRPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID NO:23), PGAIEQGPA (SEQ ID NO:24), GPSTGPRG (SEQ ID NO:25), GQGDGGRRK (SEQ ID NO:26), DGGRRKKGGWFGKHR (SEQ ID NO:27), GKHRGQGGSN (SEQ ID NO:28), GQGGSNPK (SEQ ID NO:29), NPKFENIA (SEQ ID NO:30), RSHVERTT (SEQ ID NO:31), VFVYGGSKT (SEQ ID NO:32), GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID NO:34), PQGPLRE (SEQ ID NO:35), CNIRVTVC (SEQ ID NO:36), RVTVC SFDDG (SEQ ID NO:37), [and] PPWFPPMVEG (SEQ ID NO:38) and combinations thereof, wherein the composition is in a pharmaceutically acceptable carrier for administration of the composition in an amount and mode of administration effective to induce tolerance to EBV-associated immune responses].

28. (amended) A method comprising administering to a individual a composition comprising a molecule selected from the group consisting of PPPGRRP (SEQ ID NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7), GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:13), GGSGSGPRHRDGVRRPQKRP (SEQ ID NO:14), RPQKRPS (SEQ ID NO:15), QKRPSIGCKGTHGGTG (SEQ ID NO:16), GTGAGAGARGRGG (SEQ ID NO:17), SGGGRGG (SEQ ID NO:18), RGGSGGRRGRGR (SEQ ID NO:19), RARGRGRGRGEKRPRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID NO:21), RPPPGRPPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID NO:23), PGAIEQGPA (SEQ ID NO:24), GPSTGPRG (SEQ ID NO:25), GQGDGGRRK (SEQ ID NO:26), , GKHRGQGGSN (SEQ ID NO:28), GQGGSNPK (SEQ ID NO:29), NPKFENIA (SEQ ID NO:30), RSHVERTT (SEQ ID NO:31), VFVYGGSKT (SEQ ID NO:32), GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID NO:34), PQGPLRE (SEQ ID NO:35), CNIRVTVC (SEQ ID NO:36), RVTVC SFDDG (SEQ ID NO:37), [and] PPWFPPMVEG (SEQ ID NO:38), and combinations or immunogenic portions thereof wherein the composition is in a pharmaceutically acceptable carrier for administration of the composition in an amount and mode of administration effective to induce tolerance to EBV-associated immune responses.

Please add the following new claims:29-40.

F 15ub 29. The immunogenic composition of claim 27 wherein the peptide molecules are in a pharmaceutically acceptable carrier for administration of the composition in an amount and

RESPONSE TO RESTRICTION REQUIREMENT

mode of administration effective to induce tolerance to EBV-associated immune responses wherein the composition is in a pharmaceutically acceptable carrier for administration of the composition in an amount and mode of administration effective to induce tolerance to EBV-associated immune responses.

30. The peptide molecules of claim 27 immobilized to a solid support.

31. The peptide molecules of claim 27 labeled with a detectable label.

32. The peptide molecules of claim 30 immobilized to multiwell plates.

33. The peptide molecules of claim 30 immobilized to a gel suitable for affinity chromatography.

34. The peptide molecules of claim 27 bound by autoantibodies in patients characterized by specific disorders.

35. A method for determining the likelihood that an individual has or will develop an autoimmune disorder comprising screening their antibodies for reactivity with a peptide molecule selected from the group consisting of PPPGRRP (SEQ ID NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7), GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:13), GGSGSGPRHRDGVRRPQKRP (SEQ ID NO:14), RPQKRPS (SEQ ID NO:15), QKRPSIGCKGTHGGTG (SEQ ID NO:16), GTGAGAGARGRG (SEQ ID NO:17), SGGRGRGG (SEQ ID NO:18), RGGSGRRGRGR (SEQ ID NO:19), RARGRGRGRGEKRPRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID NO:21),

RPPPGRRPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID NO:23),
PGAIEQGPA (SEQ ID NO:24), GPSTGPRG (SEQ ID NO:25), GQGDGGRRK (SEQ ID
NO:26), DGGRRKKGGWFGKHR (SEQ ID NO:27), GKHRGQGGSN (SEQ ID NO:28),
GQGGSNPK (SEQ ID NO:29), NPKFENIA (SEQ ID NO:30), RSHVERTT (SEQ ID NO:31),
VFVYGGSKT (SEQ ID NO:32), GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID
NO:34), PQGPLRE (SEQ ID NO:35), CNIRVTVC (SEQ ID NO:36), RVTVC SFDDG (SEQ
ID NO:37), PPWFPPMVEG (SEQ ID NO:38) and combinations or immunogenic portions
thereof.

36. The method of claim 35 wherein the peptide molecules are immobilized to a solid support.

37. The method of claim 35 wherein the peptide molecules are labeled with a detectable label.

38. The method of claim 36 wherein the peptide molecules are immobilized to multiwell plates.

39. The method of claim 35 wherein the peptide molecules are immobilized to a gel suitable for affinity chromatography.

40. The method of claim 35 wherein the peptide molecules are bound by autoantibodies in patients characterized by specific disorders.